Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 11/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 11/20 | 0.39 |
| ▸ | CDK4 | P11802 | 4/20 | 0.38 |
| ▸ | CCND1 | P24385 | 4/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6100232 | 0.78 | SLC6A4 (0.46) | SLC6A4SLC6A2CDK4CCND1NOTUM | |
| SCHEMBL4382022 | 0.78 | SLC6A4 (0.43) | SLC6A4SLC6A2CDK4CCND1 | |
| SCHEMBL10643066 | 0.77 | SLC6A4 (0.57) | SLC6A4SLC6A2 | |
| SCHEMBL2976520 | 0.75 | SLC6A4 (0.46) | SLC6A4SLC6A2CDK4CCND1NOTUM | |
| SCHEMBL9337141 | 0.74 | KMT2A (0.44) | SLC6A4SLC6A2NOTUM | |
| SCHEMBL9696657 | 0.74 | SLC6A4 (0.37) | SLC6A4SLC6A2CDK4CCND1 | |
| SCHEMBL22449509 | 0.71 | SLC6A2 (0.40) | SLC6A4SLC6A2CDK4CCND1 | |
| SCHEMBL27575336 | 0.71 | SLC6A2 (0.45) | SLC6A4SLC6A2CDK4CCND1NOTUM | |
| SCHEMBL9235062 | 0.70 | SLC6A4 (0.35) | SLC6A4SLC6A2CDK4CCND1 | |
| SCHEMBL4782553 | 0.70 | CDK4 (0.35) | SLC6A4SLC6A2CDK4CCND1NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-57067559-A | — | — | None | — | — | JP | disclosed |
| EP-1919471-B1 | (INDOL-3-YL)-HETEROCYCLE DERIVATIVES AS AGONISTS OF THE CANNABINOID CB1 RECEPTOR | MERCK SHARP & DOHME (NL) | 2014-01-08 | — | — | EP | disclosed |
| EP-2125795-B1 | INDOLE DERIVATIVES | MSD OSS BV (NL) | 2013-03-20 | — | — | EP | disclosed |
| US-7763732-B2 | 7-Chloro-3-({5-[N-(morpholin-1-ylcarboxamido)methyl]aminomethyl}-([1,2,4]-thiadiazol-3-yl))-1-(tetrahydropyran-4-yl)methyl-1H-indole, hydrochloride salt; treatment of pain | N.V. ORGANON (NL) | 2010-07-27 | — | — | US | disclosed |
| US-7700634-B2 | (Indol-3-yl) heterocycle derivatives as agonists of the cannabinoid CB1 receptor | N.V. ORGANON (NL) | 2010-04-20 | — | — | US | disclosed |
| US-7655645-B2 | Analgesics; neuropathic pain, cancer pain, multiple sclerosis | N.V. ORGANON (NL) | 2010-02-02 | — | — | US | disclosed |
| EP-2125795-A1 | INDOLE DERIVATIVES | N.V. Organon (NL) | 2009-12-02 | — | — | EP | disclosed |
| US-20080207598-A1 | INDOLE DERIVATIVES | N.V. ORGANON (NL) | 2008-08-28 | — | — | US | disclosed |
| WO-2008101995-A1 | INDOLE DERIVATIVES | N.V. ORGANON (NL) | 2008-08-28 | — | — | WO | disclosed |
| EP-1919471-A1 | (INDOL-3-YL)-HETEROCYCLE DERIVATIVES AS AGONISTS OF THE CANNABINOID CB1 RECEPTOR | N.V. Organon (NL) | 2008-05-14 | — | — | EP | disclosed |
| US-RE32761-E | ANALGESICS, ANTIRHEUMATIC AND ANTIINFLAMMATORY AGENT | STERLING DRUG INC. (US) | 1988-10-04 | — | — | US | disclosed |
| US-RE32761-E | ANALGESICS, ANTIRHEUMATIC AND ANTIINFLAMMATORY AGENT | STERLING DRUG INC. (US) | 1988-10-04 | — | — | US | disclosed |
| US-4634776-A | ANALGESIC, ANTIRHEUMATIC, ANTIINFLAMMATORY | STERLING DRUG, INC. (US) | 1987-01-06 | — | — | US | disclosed |
| US-4634776-A | ANALGESIC, ANTIRHEUMATIC, ANTIINFLAMMATORY | STERLING DRUG, INC. (US) | 1987-01-06 | — | — | US | disclosed |
| US-4581354-A | ANALGESICS;ANTI-RHEUMATIC AND ANTI-INFLAMMATORY AGENTS | STERLING DRUG INC. (US) | 1986-04-08 | — | — | US | disclosed |
| US-4581354-A | ANALGESICS;ANTI-RHEUMATIC AND ANTI-INFLAMMATORY AGENTS | STERLING DRUG INC. (US) | 1986-04-08 | — | — | US | disclosed |
| EP-0171037-A2 | 3-Carbonyl-1-aminoalkyl-1H-indoles useful as analgesics and preparation thereof | STERLING WINTHROP INC. (US) | 1986-02-12 | — | — | EP | disclosed |
| EP-0171037-A2 | 3-Carbonyl-1-aminoalkyl-1H-indoles useful as analgesics and preparation thereof | STERLING WINTHROP INC. (US) | 1986-02-12 | — | — | EP | disclosed |
| JP-S5767559-A | PRODUCTION OF INDOLE DERIVATIVE | TORAY IND INC | 1982-04-24 | — | — | JP | disclosed |
| US-4138292-A | ENZYMES OR MICROORGANISMS IN A SULFATED POLYSACCHARIDE GEL | TANABE SEIYAKU CO., LTD. (JP) | 1979-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207598-A1 | INDOLE DERIVATIVES | CNR1, CNR2, OPRD1 | SLC6A4 632/4885SLC6A2 1918/4885CDK4 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.